Yahoo
OTC Markets OTCPK - Delayed Quote USD

Hemagen Diagnostics, Inc. (HMGN)

0.0002 0.0000 (0.00%)
At close: November 2 at 4:00:00 PM EST
Chart Range Bar
Loading chart for HMGN
  • Previous Close 0.0002
  • Open 0.0150
  • Bid --
  • Ask --
  • Day's Range 0.0150 - 0.0150
  • 52 Week Range 0.0001 - 0.1251
  • Volume 50,000
  • Avg. Volume 307
  • Market Cap (intraday) 3,100
  • Beta (5Y Monthly) 1,214.01
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Hemagen Diagnostics, Inc. provides human and veterinary diagnostic services worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its proprietary test kits are used to aid in the diagnosis of certain autoimmune and infectious diseases. It also provides human diagnostics, such as universal IFA components; supplies, controls and calibrators, accessories, and H-rotors; reagents, electrodes, equipment; and specialty assays, including Chagas, acute phase proteins, and cytokines. In addition, the company offers veterinary diagnostic products, such as equipment, reagents, supplies, accessories, and electrodes in chemistry, hematology, and electrolyte areas. Its products are used in laboratories, hospitals and blood banks. Hemagen Diagnostics, Inc. was incorporated in 1985 and is based in Columbia, Maryland.

www.hemagen.com

15

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

HMGN
0.00%
S&P 500 (^GSPC)
10.57%

1-Year Return

HMGN
100.00%
S&P 500 (^GSPC)
10.46%

3-Year Return

HMGN
100.00%
S&P 500 (^GSPC)
73.67%

5-Year Return

HMGN
100.00%
S&P 500 (^GSPC)
62.40%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -22.45%

  • Return on Assets (ttm)

    -10.27%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    4.04M

  • Net Income Avi to Common (ttm)

    -907.32k

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    66.29k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -115.85k

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: